You are here
Zelda Expands Its Breast Cancer Research Collaboration with Complutense University Madrid Health Medical News 

Zelda Expands Its Breast Cancer Research Collaboration with Complutense University Madrid

PERTH, Australia, July 31, 2017 /Weed Wire/ — The Board of Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company) is pleased to announce it has expanded its research collaboration with Complutense University, based on positive initial research results from its breast cancer research programme.

Zelda has reported positive results from its initial proof of concept study (announced 30 November 2016) and follow-on studies (announced 2 June 2017), on its pre-clinical research on cannabinoids as anti-cancer agents. The results showed a number of key findings, but most importantly that there were anti-cancer effects observed across a range of different breast cancer cell lines using Zelda’s formulations. The next stage of this research will continue with both in vitro and in vivo studies.

Read the full article

Related posts